An interventional study of SIRENS in Dementia, Elder Abuse and Elder Neglect, sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,051 studies in Dementia with a site in United States — 211 open to participants now, 276 under way, 15 of them phase 3. Dementia · United States.
Among the 1,051 studies in Dementia with a site in United States, this one is the 592nd largest by planned enrollment of the 846 interventional ones that give a count, is one of 65 that started in 2026, is one of 562 with no phase, reaches primary completion later than 109 of the 275 other live ones, and was the 974th registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →211 of the 1,051 studies in Dementia with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 50+ · Women only · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 65+
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 50–100 · Healthy volunteers
The Cleveland Clinic · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 21 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,051 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 146 · Phase 3 79 · Phase 4 33
First in 1981; this study’s year is marked. 65 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 93 across the 846 interventional studies, 200 across the 200 observational. Of the 715 that completed or were terminated, 309 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
191 of 1,051 have an industry lead sponsor. The 10 most frequent:
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
Weill Medical College of Cornell University has 9 studies filed under Dementia — fewer than ten, so there is no comparison to draw.
107 of the studies in Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT07430371Rendever, Inc.Virtual Reality for Caregiver Assembly, Relief, Empowerment, and Support (VR-CARES) | 2026-11 |
| NCT06095284Virginia Commonwealth UniversityPrescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic | 2026-11-30 |
| NCT06298474Hopeful AgingThe BRAIN App (Phase 2 SBIR) | 2026-11-30 |
| NCT07859865Drexel UniversityMindfulness-based Movement Therapy for Persons With Dementia and Family Caregivers | 2026-11-30 |
Add all 107 to your calendar (.ics) → With an account.
Among the 1,051 studies in Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research project has three main goals:
(1) To create a new screening tool that helps primary care doctors spot signs of neglect in older adults with dementia. (2) To design a support program that can be delivered both in person and through a mobile app on Android phones. (3) To run a clinical trial with three groups of participants to find out how effective the screening tool is on its own, and how effective it is when combined with the support program-compared to standard care.
This current phase of the project focuses on parts of goals 1 and 2, as described below.
Elder abuse is common and has serious health consequences but is under-recognized and under-reported. Older adults with dementia are at much higher risk of mistreatment than other older adults, and the risk of mistreatment has been shown to be greater with increasing severity of dementia. This mistreatment is usually perpetrated by caregivers.
Screening for elder mistreatment and initiation of intervention in primary care clinics may be helpful, but few evidence-based tools or strategies exist. As few tools exist that may be effectively used in a busy clinical setting, evidence of the impact of screening and potential subsequent intervention on patient-important outcomes is lacking. Further, existing tools were developed for and studied in cognitively intact older adults and may not be appropriate for older adults with AD/ADRD.
In addition, elder mistreatment includes physical abuse, sexual abuse, verbal/emotional/psychological abuse, financial exploitation, and caregiver neglect. These different types of elder mistreatment represent very different phenomena, occur in various groups of older adults, and respond to very different intervention strategies. These discrepancies have made connecting positive identifications of mistreatment in the primary care setting to the next steps, including interventions, very challenging. Focusing on an intervention for caregiver neglect in older adults with dementia has the potential to address these challenges. Given that the severity of dementia represents a significant risk factor in the caregiving relationship, our goal is to provide support for dementia caregivers.
The criteria were revised on the registry on Nov 6, 2026. See what changed
Caregiver Inclusion Criteria
Provides care for a patient of Weill Cornell Medicine/NewYork-Presbyterian who meets the following criteria: (pilot only)
Caregiver Exclusion Criteria
The SIRENS intervention is a technology intervention designed specifically for caregivers of those with dementia, providing them with easy access to expert-reviewed information and helpful resources. The content includes take-home messages summarizing the main points discussed and a goal-setting feature that encourages the care givers to establish small, actionable goals.
Behavioral: SIRENS
The SIRENS intervention is a technology intervention designed specifically for caregivers of those with dementia, providing them with easy access to expert-reviewed information and helpful resources. The content includes take-home messages summarizing the main points discussed and a goal-setting feature that encourages the care givers to establish small, actionable goals.
Perceived system feasibility, acceptability, and usability of the SIRENS intervention as measured by the Mean Difference in Score of the Program Evaluation Questionnaire.
System feasibility, acceptability and usability will be assessed in the Program Evaluation Questionnaire. This is based on the Davis Perceived Usefulness, Perceived Ease of Use, and User Acceptance Scale. Response options range from 1= Strongly Disagree to 7= Strongly agree. Questions include those asking about the technology and components of the intervention. Total scores range from 23 to 161. Higher scores indicate greater user acceptance of the technology.
Time frame: 1 week post-intervention
Perceived system feasibility, acceptability, and usability of the SIRENS intervention as measured by a qualitative interview assessment
System feasibility, acceptability and usability will be assessed in care partner participants using a semi-structured interview. Thematic analyses will be used to assess qualitative interviews.
Time frame: 1-week post intervention
Mean difference in score of caregiver burden, as measured by the Zarit Caregiver Burden Assessment.
Caregiver burden will be assessed in care partner participants using the reliable and valid Zarit Caregiver Burden Assessment. Response options range from 0= Never to 4= Nearly always. Questions include those asking about relationship with the care recipient and stress. Overall scores range from 0 to 48, with higher scores indicating more caregiver burden.
Time frame: Baseline and 1 week post-intervention
Mean difference in score of caregiver quality of life, as measured by the Quality of Life Inventory
Caregiver quality of life will be assessed in care partner participants using the reliable and valid Quality of Life Inventory. Questions include those asking about importance (on a 3-point rating scale, higher value indicating more importance) and satisfaction (on a 6-point rating scale, higher value indicating more satisfaction) of life domains. Importance scores are multiplied by satisfaction scores for each domain, and then these scores are summed to determine the overall score. Overall scores range from -96 to 96, with higher scores indicating higher quality of life.
Time frame: Baseline and 1 week post-intervention
Mean difference in score of caregiver preparedness, as measured by the Caregiver Preparedness Scale
Caregiver preparedness will be assessed in care partner participants using the Preparedness Scale. Response options range from 0= Not at all prepared to 4= Very well prepared. Overall scores range from 0 to 24 with higher scores indicating more feelings of preparedness.
Time frame: Baseline and 1 week post-intervention
Mean difference in score of caregiving self-efficacy, as measured by the Caregiving Self-Efficacy Scale
Caregiving self-efficacy will be measured in care partner participants by a modified Caregiving Self-Efficacy Scale. Response options range from 0= Can not do at all to 100= Certainly can do. Overall scores range from 0 to 900 with higher scores indicating more confidence.
Time frame: Baseline and 1 week post-intervention
Mean difference in score of caregiver depression, as measured by the Center for Epidemiologic Studies Depression Scale
Caregiver depression will be assessed in care partner participants using the reliable and valid Center for Epidemiologic Studies Depression Scale. Response options range from 0= Rarely or none of the time to 3= Most or almost none of the time. Overall scores range from 0 to 60 with higher scores indicating greater depressive symptoms.
Time frame: Baseline and 1 week post-intervention
Plan to share: Yes — The investigators plan for resource sharing is based on the National Institutes of Health/National Institute on Aging (NIH/NIA) Data Sharing Policy. The investigators plan, consistent with the NIH goals of data sharing, is to promote use of the rich SIRENS database by the larger research community as this will further the impact of SIRENS and expand possibilities for collaboration. It will also allow other researchers to expedite the translation of the research findings into knowledge, products, and procedures. Further, the plan is devised to make the data as widely and freely available as possible while at the same time safeguarding the privacy of participants and protecting confidential and proprietary data.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: The data from research projects will be made available no later than acceptance of publication of the main findings from the final data set. There is no end date to access the data from the research projects.
Access criteria: The investigators agree to share the data with researchers working under an institution with Federal Wide Assurance who agree to a data sharing agreement that stipulates protection of participant privacy and data confidentiality, acknowledgement of SIRENS, that the data will be used for research purposes only, and that the data will not be transferred to other users. The computerized data will include raw data, derived variables, all necessary documentation as described in the National Archive of Computerized Data on Aging depositor agreement. All data will be de-identified. The investigators will follow the guides published by the US Department of Health and Human Services in this respect. Each data set will include data documentation to ensure that others can use the data set and to minimize confusion. Information about where and how to locate and access the data will be available in any publications and presentations authored by SIRENS investigators.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 5 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Sep 2026 → Oct 2026, primary completion Dec 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →